Phase 1CompletedAge-related condition

Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer

Multicenter, Randomized, Single-blind Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer

Sponsor
Panacela Labs LLC (Industry)
Enrollment
32 enrolled
Conditions
Prostate Cancer
Interventions
Mobilan (M-VM3); Placebo
Ages
adults, older adults
Registry
NCT02654938

Full record on ClinicalTrials.gov

From the registry

Phase I single-blinded, randomized, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of single injections of ascending doses of investigational drug product Mobilan (М-VM3) administered directly into the prostate of patients with prostate cancer.

Primary outcomes

  • Frequency and intensity of adverse events (according to CTCAE v 4.03 classification)

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started